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by diminished pleasure and depression which plays a key
role in drug relapse and addictive behaviors. There is no eﬃ-
cient treatment for AW-induced depression and underpin-
ning mechanisms were not well determined. Considering
both transient receptor potential cation channel, subfamily
V, member 1 (TRPV1) and N-Methyl-D-aspartate (NMDA)
receptors contribute to pathophysiology of mood and addic-
tive disorders, in this study, we investigated the role of
TRPV1 and NMDA receptors in mediating depressive-like
behaviors following AW in male mice. Results revealed that
administration of capsaicin, TRPV1 agonist, (100 lg/mouse,
i.c.v.) and MK-801, NMDA receptor antagonist (0.005 mg/kg,
i.p.) reversed AW-induced depressive-like behaviors in
forced swimming test (FST) and splash test with no eﬀect
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122doses of MK-801 (0.001 mg/kg, i.p.) and capsaicin
(10 lg/mouse, i.c.v) exerted antidepressant-like eﬀects in
behavioral tests. Capsazepine, TRPV1 antagonist,
(100 lg/mouse, i.c.v) and NMDA, NMDA receptor agonist
(7.5 mg/kg, i.p.) abolished the eﬀects of capsaicin and MK-
801, respectively. None of aforementioned treatments had
any eﬀect on behavior of control animals. Collectively, our
ﬁndings showed that activation of TRPV1 and blockade of
NMDA receptors produced antidepressant-like eﬀects in
male mice following AW, and these receptors are involved
in AW-induced depressive-like behaviors. Further, we found
that rapid antidepressant-like eﬀects of capsaicin in FST and
splash test are partly mediated by NMDA receptors.  2016
Published by Elsevier Ltd on behalf of IBRO.
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INTRODUCTION
Several lines of evidence indicate that withdrawal from
psychostimulants induces behavioral and neurochemical
alterations (Renoir et al., 2012; Che et al., 2013). With-
drawal from stimulants is accompanied by dysphoric state
which contributes to drug-seeking behavior and relapse,
and causes treatment failure in individuals with stimulant
dependence (Koob et al., 1998; Oleson et al., 2014).
Recent evidence suggests that applying animal models
of psychostimulants withdrawal provided appropriate
tools for understanding underlying mechanisms involved
in mood disorders namely depression (Barr and Markou,
2005). Amphetamine (AMPH)-style drugs are potent psy-
chostimulants which their acute abstinence is associated
with depressive-like behaviors such as motivational
impairment and behavioral despair (Cryan and Holmes,
2005). In animal studies, it has been proposed that
depressive-like behaviors following AMPH withdrawal
(AW) are associated with abnormal neurotransmission
in the regions of the brain relevant to depression (Sulzer
et al., 2005). In this regard, it has been accepted that
acute phase of psychostimulant withdrawal is associated
with abnormal glutamatergic neurotransmission in several
brain areas that may be associated with negative aﬀect
observed in early recovery state (Kalivas and Volkow,
2005; D’Souza and Markou, 2010). Further, recent stud-
ies have shown that chronic administration of stimulants
(such as AMPH) enhances hippocampal glutamatergic
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Methyl-D-aspartate (NMDA) receptors (D’Souza and
Markou, 2010; Underhill et al., 2014). Increase in sensitiv-
ity to glutamate following AW plays a crucial role in behav-
ioral diﬃculties observed after drug cessation (Kalivas
and Volkow, 2005; Koltunowska et al., 2013). Evidence
suggests that impairment of dopaminergic system activity
contribute to diﬃculties with self-care and motivation fol-
lowing AW (Rossetti et al., 1992). It is well-established
that serotonergic drugs are ineﬃcient for treatment of
depression in acute phase of AW (Zorick et al., 2011).
In this context, emerging lines of research suggest that
glutamatergic system can be an appropriate therapeutic
target in moderating dysphoric state following AW
(D’Souza and Markou 2010; Iijima et al., 2013; Fuller
et al., 2015). Although it has been well documented that
glutamatergic system plays an important role in AMPH-
induced behavioral abnormalities, underlying mecha-
nisms by which acute AMPH abstinence exerts its
depressant eﬀects is not clear.
Evidence indicates that transient receptor potential
cation channel, subfamily V, member 1 (TRPV1) is
involved in pathophysiology of mood disorders (Di Marzo
et al., 2008; Terzian et al., 2009; Ho et al., 2012). In this
regard, both TRPV1 agonists and antagonist have been
reported to have antidepressant eﬀects by diﬀerent mech-
anisms including involvement of NMDA receptors (Manna
andUmathe, 2012; Abdelhamid et al., 2014). Furthermore,
it has been reported that TRPV1 plays a role in pathophys-
iology of addiction (Wescott et al., 2013; Martins et al.,
2014). Expression of TRPV1 undergoes alterations follow-
ing stimulant administration in the brain, (Tian et al., 2010)
and also these channels have been shown to have a regu-
latory role in morphine-induced reward (Nguyen et al.,
2014). Since both NMDA and TRPV1 receptors are impli-
cated in behavioral abnormalities relevant to depression
and addiction, their roles in mediating depressive-like
behaviors following AW have remained elusive.
Considering that dysphoria following AMPH
abstinence is involved in drug seeking and relapse, we
aimed to investigate the eﬀects of capsaicin, a selective
TRPV1 receptor agonist, on depressive-like behaviors
following AW in male mice. In this regard, we
challenged the hypothesis that TRPV1 and NMDA
receptors play a role in depressive-like behaviors
following acute AW in male adult mice.EXPERIMENTAL PROCEDURES
Animals
MaleNMRImice (Pasteur Institute, Tehran, Iran), weighing
25–30 g, were used. Animals were housed under standard
conditions (temperature: 22 ± 2 C, humidity: 50 ± 10%,
12-h light–dark cycle, and free access to food and water).
All procedures in this study were carried out in
accordance with the National Institutes of Health (NIH)
Guide for the Care and Use of Laboratory Animals (NIH
publication # 80-23) and institutional guidelines for animal
care and use (Department of Pharmacology, School of
Medicine, TUMS).Stereotaxic surgery
Animals were anesthetized by a ketamine (100 mg/kg)
and xylazine (10 mg/kg) subsequently submitted to a
stereotaxic frame. The animals were implanted with a
22-gauge stainless-steel guide cannula placed above
the right lateral cerebral ventricle (stereotaxic co-
ordinates were: AP, 0.9 mm to the bregma; L, 1.4 mm
lateral to the midline; V, 2.5 mm below the top of the
skull). The cannula was ﬁxed to the skull using one
screw and dental cement. A stylet was inserted into the
guide cannula to keep it open prior to injections.
Implantation was performed at least ﬁve days before
initiation of the chronic AMPH treatment.Drugs
Following drugs were used: D-amphetamine sulfate and
MK-801 (Sigma-Aldrich, St. Louis, MO, USA), Capsaicin
(Fluka, Switzerland), Capsazepine (Tocris, UK), N-
Methyl-D-aspartate or NMDA (Tocris, UK). Capsaicin
and capsazepine were dissolved in Tween 80: DMSO:
saline in 1:2:7 ratios and administered i.c.v 15 min
before the examination. MK-801 and NMDA
(intraperitoneally, i.p.) were dissolved in saline and
administered 15 min before the test. D-amphetamine
sulfate was dissolved in saline and administered for ﬁve
consecutive days (i.p.) in the volume of 10-ml/kg of
mouse weight.Open-ﬁeld test (OFT)
The OFT was used to evaluate the locomotion of animals
in response to AW and diﬀerent treatments according to
the criteria described by Amiri et al. (2015a). The open-
ﬁeld apparatus was white opaque Plexiglas
(50 cm  50 cm  30 cm), which was dimly illuminated.
Each mouse was placed gently on the center square
(30 cm  30 cm), and behaviors were recorded by a cam-
era for 5 min and were analyzed by Ethovision software
version 8.5 (Noldus, Netherlands). The surface of the
apparatus was cleaned with 70% ethanol after each
experiment. The distance moved (horizontal activity)
and the number of rearings (vertical activity) were
evaluated.Forced swimming test (FST)
We used FST to evaluate the immobility time of animals in
response to an acute inescapable stress challenge
reﬂecting behavioral despair (Cryan and Holmes, 2005;
Haj-Mirzaian et al., 2015). In brief, mice were separately
placed in an open cylinder-shaped ﬂask (diameter:
10 cm, height: 25 cm), containing 19 cm water at 23
± 1 C. Mice were permitted to swim for 6 min and the
immobility time was recorded throughout the last 4 min
of the test. Each mouse was judged to be immobile when
it ceased struggling and stayed ﬂoating motionless in the
water, making only those movements necessary to keep
its head above water.
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Splash test is accepted tool to evaluate the motivational
and self-care diﬃculties as core symptoms of
depression in rodents (David et al., 2009; Amiri et al.,
2015b). In this test, grooming behavior of mice, which
can be considered as an indirect measure of palatable
solution intake, was measured. A 10% sucrose solution
was squirted on the dorsal coat of animals in their home
cage and mice were videotaped for 5 min. The total
grooming activity time was recorded during 5 min after
the sucrose vaporization. Grooming activity consists of
nose/face grooming, head washing and body grooming.Experimental design
Twenty-four hours after the last injection of AMPH (5 mg/
kg) or saline, mice were divided into two groups (6–8 mice
in each group): (1) AW and (2) Controls. Locomotion (in
the OF), immobility time (in the FST) and grooming
activity time (in the splash test) were evaluated in both
groups. In order to determine the sub-eﬀective doses of
drugs, various doses of vehicle, capsaicin (10, 100, 200
and 300 lg/mouse, i.c.v), capsazepine (100 and
200 lg/mouse, i.c.v), NMDA (7.5 and 75 mg/kg, i.p.) and
MK-801 (0.001, 0.005, 0.05 mg/kg, i.p) and their
combinations were applied in both groups.Fig. 1. Eﬀect of amphetamine-withdrawal (AW) on depressive-like behaviors
time in the splash test (B), total distance moved in the OF (C), and number o
were analyzed using t-test. ***P< 0.001 compared with the control group.For investigation of possible involvement of TRPV1
channels in the antidepressant-like eﬀects of capsaicin,
we treated AW mice with sub-eﬀective dose of
capsazepine/vehicle (100 lg/mouse, 5 min prior to
capsaicin injection, i.c.v) and capsaicin/vehicle
(100 lg/mouse, 15 min prior to tests, i.c.v). In order to
evaluate the possible involvement of NMDA receptors in
antidepressant-like eﬀects of capsaicin, we used the co-
administration of sub-eﬀective dose of capsaicin/vehicle
(10 lg/mouse, 15 min prior to tests, i.c.v) and MK-801/
saline (0.001 mg/kg, 45 min prior to tests, i.p.).
Furthermore, we co-treated mice with NMDA/saline
(7.5 mg/kg, 30 min prior to tests, i.p.) and capsaicin/
vehicle (100 lg/mouse, 15 min prior to tests, i.c.v) to
ensure the contribution of NMDA receptors in eﬀects of
capsaicin. Doses of each drug were chosen according to
our pilot and previous studies (Manna and Umathe, 2012;
Salehi-Sadaghiani et al., 2012; Haj-Mirzaian et al., 2015)Statistics
SPSS (version 21) and GraphPad prism statistical
(version 6.1) softwares were used for data analysis and
ﬁgure creation. The diﬀerences in immobility time,
grooming activity time and locomotor activity between
animal groups were analyzed by a one-way ANOVA,
followed by Tukey’s post hoc test. P< 0.05 was
considered signiﬁcant in all experiments.. Eﬀect of AW, on the immobility time in the FST (A), grooming activity
f rearings in the OF (D). Values are expressed as mean ± S.E.M and
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AW provoked depressive-like behaviors in mice
Helplessness and hopelessness are observed in
depressed people in response to stressful conditions.
Exposing depressed animals to an acute inescapable
condition such as FST, results in an increase in
immobility time. Fig. 1A shows that the immobility time
increased in AW group when compared to the control
group in the FST (t= 4.435, df = 12, P< 0.001,
Fig. 1A). Motivational and self-care diﬃculties are
considered as main symptoms of depression that have
been translated in rodents by a reduction in grooming
time in the splash test. Results show that acute AW
caused a signiﬁcant reduction in grooming activity time
in the splash test (t= 15.29, df = 14, P< 0.001,
Fig. 1B). In the OF, there is no signiﬁcant diﬀerences in
the total distance moved (horizontal activity) (t= 0.113,
df = 14, P> 0.05, Fig. 1C) and number of rearings
(vertical activity) (t= 0.485, df = 14, P> 0.05, Fig. 1D)
between AW and control mice.Capsaicin and not capsazepine attenuated the
depressant eﬀect of AW
We assessed the eﬀects of various doses of capsaicin
(100, 200, and 300 lg/mouse, i.c.v.) and capsazepine
(100 and 200 lg/mouse, i.c.v.) on depression related
behaviors (Fig. 2A, C, E, G). An ANOVA revealed that
there were signiﬁcant diﬀerences between the treated
groups in FST (F(6, 42) = 307.8, P< 0.001, Fig. 2A)
and splash test (F(6, 48) = 2.641, P< 0.05, Fig. 2C),
but not in the distance moved in OF (F(6, 49) = 0.1071,
P> 0.05, Fig. 2E), and number of rearings in OF (F(6,
49) = 0.1082, P> 0.05, Fig. 2G).
In the FST, Tukey’s analysis showed that
administration of capsaicin (200 and 300 lg/mouse)
(P< 0.001) and capsazepine (200 lg/mouse)
(P< 0.001) to normal mice signiﬁcantly decreased the
immobility time in comparison with vehicle-treated mice
(Fig. 2A). Treatment with the lower doses, capsaicin
100 lg/mouse and capsazepine 100 lg/mouse, did not
produce signiﬁcant alterations in the immobility time of
mice when compared with vehicle-treated animals
(P> 0.05, Fig. 2A). In the splash test, Tukey’s analysis
showed that administration of capsaicin (200 and
300 lg/mouse) (P> 0.05) and capsazepine
(200 lg/mouse) (P> 0.05) did not alter the grooming
activity of control animals when compared to vehicle-
treated group (Fig. 2C). Similarly, administration of the
lower doses of capsaicin (100 lg/mouse) and
capsazepine (100 lg/mouse) had no signiﬁcant eﬀect on
grooming activity time of control groups (P> 0.05,
Fig. 2C). In the OF, administration of the applied doses
of each drugs did not alter the both total distance
moved and number of rearings of control mice in
comparison with vehicle-treated group (P> 0.05,
Fig. 2E, G). Also, our results show that vehicle
treatment did not aﬀect the behaviors of normal mice in
all applied behavioral tests (P> 0.05).In the next step, we evaluated the eﬀects of the sub-
eﬀective doses of each drug, on depressive-like and
locomotion behaviors in the AW animals (Fig. 2B, D, F,
H). An ANOVA revealed that there were signiﬁcant
diﬀerences between the treated groups in FST (F(4, 30)
= 5.505, P< 0.01, Fig. 2B) and splash test (F(4, 27)
= 31.69, P< 0.001, Fig. 2D), but not in the distance
moved in OF (F(4, 35) = 0.3727, P> 0.05, Fig. 2F),
and number of rearings in OF (F(4, 35) = 0.0557,
P> 0.05, Fig. 2H).
Tukey’s analysis shows that administration of
capsaicin (100 lg/mouse, but not 10 lg/mouse)
signiﬁcantly reduced the duration of immobility in the
AW animals when compared with the vehicle-treated
group (P< 0.01, Fig. 2B). However, capsazepine
(100 lg/mouse) did not produce any signiﬁcant
alterations in immobility time of mice undergoing AW in
the FST (P> 0.05, Fig. 2B). In the splash test, tukey’s
analysis shows that administration of capsaicin
(100 lg/mouse, but not 10 lg/mouse) enhanced the
grooming activity time of AW animals when compared to
vehicle-treated group (P< 0.001, Fig. 2D). But,
capsazepine (100 lg/mouse) did not increase the
grooming activity time of AW groups (P> 0.05,
Fig. 2D). In the OF, injection of the applied doses of
each drug did not change neither total distance moved
nor number of rearings of AW animals when compared
to the vehicle-treated groups (P> 0.05, Fig. 2F, H).
Likewise the last part, data showed that vehicle
treatment did not change the behavior of animals in all
applied behavioral tests (P> 0.05).
Depressant eﬀects of AW were reversed by MK-801
treatment
In order to assess the role of NMDA receptors in AW-
induced depressive-like behaviors, we investigated the
eﬀects of diﬀerent doses of MK-801 and NMDA. At ﬁrst,
we investigated the possible eﬀect of treatments in
control animals. An ANOVA shows that there were
signiﬁcant diﬀerences between the treated groups in
FST (F(5, 36) = 6.673, P< 0.001, Fig. 3A) and splash
test (F(5, 42) = 6.749, P< 0.001, Fig. 3C), but not in
the distance moved in OF (F(5, 42) = 0.065, P> 0.05,
Fig. 3E), and number of rearings in OF (F(5, 42)
= 0.071, P> 0.05, Fig. 3G).
Tukey’s analysis showed that administration of MK-
801 (0.05 mg/kg, i.p.) signiﬁcantly improved the mice
behavior in FST (P< 0.001, Fig. 3A) as well as splash
test (P< 0.05, Fig. 3C). However, administration of the
lower doses of MK-801 (0.005 and 0.001 mg/kg) did not
alter the immobility time and grooming activity time of
control animals in comparison with saline-treated group
(P> 0.05). An analysis revealed that administration of
NMDA (7.5 and 75 mg/kg, i.p.) did not signiﬁcantly
increase the immobility time of control mice in the FST
(P> 0.05, Fig. 3A). Also, administration of NMDA (7.5
and 75 mg/kg) had no eﬀect on the grooming activity
time of animals in splash test (P> 0.05, Fig. 3C).
Moreover, MK-801 and NMDA treatments did not aﬀect
the both locomotor activities of control mice in the OF
(P> 0.05, Fig. 3E, G).
Fig. 2. Eﬀect of capsaicin and capsazepine treatments on depressive-like behaviors. Eﬀects of capsaicin (100, 200, and 300 lg/mouse, i.c.v.) and
capsazepine (100 and 200 lg/mouse, i.c.v.) on the immobility time in the FST (A, B), grooming activity time in the splash test (C, D), total distance
moved in the OF (E, F), and number of rearings in the OF (G, H) in the control and amphetamine-withdrawn (AW) animals. Values are expressed as
mean ± S.E.M and were analyzed using a one-way ANOVA followed by Tukey’s post hoc test. **P< 0.01 and ***P< 0.001 compared with the
vehicle-treated control group (V group) in each ﬁgure.
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Fig. 3. Eﬀect of MK-801 and NMDA treatments on depressive-like behaviors. Eﬀects of MK-801 (0.001, 0.005, and 0.05 mg/kg, i.p.) and NMDA (7.5
and 75 mg/kg, i.p.) on the immobility time in the FST (A, B), grooming activity time in the splash test (C, D), total distance moved in the OF (E, F),
and number of rearings in the OF (G, H) in the control and amphetamine-withdrawn (AW) animals. Values are expressed as mean ± S.E.M and
were analyzed using a one-way ANOVA followed by Tukey’s post hoc test. **P< 0.01 and ***P< 0.001 compared with the saline-treated control
group (S group) in each ﬁgure.
S. Amiri et al. / Neuroscience 329 (2016) 122–133 127
128 S. Amiri et al. / Neuroscience 329 (2016) 122–133Secondly, we investigated the eﬀects of the sub-
eﬀective doses of MK-801 and NMDA, on animal
behaviors in the AW groups (Fig. 3B, D, F, H). An
ANOVA revealed that there were signiﬁcant diﬀerences
between the treated groups in FST (F(3, 24) = 6.567,
P< 0.01, Fig. 3B) and splash test (F(3, 24) = 8.648,
P< 0.001, Fig. 3D), but not in the distance moved in
OF (F(3, 28) = 0.2054, P> 0.05, Fig. 3F), and number
of rearings in OF (F(3, 28) = 0.0368, P> 0.05, Fig. 3H).
Tukey’s analysis showed that administration of MK-
801 (0.005 mg/kg) signiﬁcantly reversed the depressant
eﬀect of AW in FST (P< 0.01, Fig. 3B) and splash test
as well (P< 0.01, Fig. 3D). However, administration of
the lower dose of MK-801 (0.001 mg/kg) did not alter
either the immobility or grooming time of AW mice in
comparison with saline-treated group (P> 0.05). Also,
an analysis demonstrated that NMDA (7.5 mg/kg) had
no eﬀect on the immobility and grooming activity times
of AW animals in the behavioral tests (P> 0.05,
Fig. 3B, D). In the OF, administration of MK-801 and
NMDA did not alter total distance moved and number of
rearings of AW mice in comparison with saline-treated
group (P> 0.05, Fig. 3F, G). It is important to note that
administration of NMDA (75 mg/kg) to AW mice
correlated with signiﬁcant seizure-like behaviors
(running and loss of writing ability) and mortality in mice
(3 of 6). Thus, we only administered NMDA (7.5 mg/kg)
to mice.Capsazepine abolished the antidepressant-like
eﬀects of capsaicin in AW mice
Fig. 4 shows the eﬀects of capsazepine and capsaicin co-
treatment on the behavioral tests. An ANOVA showed
that there were signiﬁcant diﬀerences between all
treated groups in FST (F(7, 48) = 7.898, P< 0.001,
Fig. 4A) and splash test (F(7, 50) = 69.72, P< 0.001,
Fig. 4B), but not in the distance moved in OF (F(7, 56)
= 0.2287, P> 0.05, Fig. 4C), and number of rearings
in OF (F(7, 56) = 0.078, P> 0.05, Fig. 4D).
An analysis revealed that treatment with capsazepine
(100 lg/mouse) abolished the eﬀects of capsaicin
(100 lg/mouse) in the FST and splash test. There were
signiﬁcant diﬀerences between capsaicin
(100 lg/mouse) and capsaicin (100 lg/mouse)
+ capsazepine (100 lg/mouse) administered groups in
the both FST (P< 0.001, Fig. 4A) and splash test
(P< 0.01, Fig. 4B). However, capsazepine and
capsaicin injections did not aﬀect the behavior of control
mice in the FST and splash test (P> 0.05, Fig. 4A, B).
In addition, administration of applied drugs did not alter
total distance moved and number of rearings of control
and AW mice in comparison with vehicle-treated group
(P> 0.05, Fig. 4C, D).Antidepressant-like eﬀects of capsaicin are partly
related to NMDA receptors
In order to evaluate the possible role of NMDA receptors
in the antidepressant eﬀect of TRPV1 agonist, the sub-
eﬀective doses of NMDA receptor antagonist/agonist
were administered alone or in combination withcapsaicin. An analysis showed that there were
signiﬁcant diﬀerences between all treated groups in FST
(F(7, 48) = 5.984, P< 0.001, Fig. 5A) (F(7, 48)
= 6.667, P< 0.001, Fig. 6A) and splash test (F(7, 51)
= 39.00, P< 0.001, Fig. 5B) (F(7, 51) = 52.78,
P< 0.001, Fig. 6B), but not in the distance moved in
OF (F(7, 56) = 0.1227, P> 0.05, Fig. 5C) (F(7, 56)
= 0.2089, P> 0.05, Fig. 6C), and number of rearings
in OF (F(7, 56) = 0.1187, P> 0.05, Fig. 5D) (F(7, 56)
= 0.1074, P> 0.05, Fig. 6D). Tukey’s analysis showed
that injection of capsaicin (10 lg/mouse), MK-801
(0.001 mg/kg), and NMDA (7.5 mg/kg) did not alter the
behavior of animals in both experimental groups
(P> 0.05).
Data showed that co-administration of MK-801
(0.001 mg/kg) with capsaicin (10 lg/mouse) signiﬁcantly
reduced the immobility time of AW mice when
compared to vehicle-treated group in the FST
(P< 0.001, Fig. 5A). In addition, administration of MK-
801 (0.001 mg/kg) signiﬁcantly augmented the
antidepressant-like eﬀect of capsaicin (10 lg/mouse) in
AW animals in splash test (P< 0.001, Fig. 5B).
Analysis showed that none of the above-mentioned
treatments changed the behaviors of the control mice in
the FST and splash test (P> 0.05). Also, MK-801 and
capsaicin either alone or in combination did not change
the total distance moved and number of rearings of
animals in the OF (P> 0.05, Fig. 5C, D).
Treatment with NMDA (7.5 mg/kg) abolished the
antidepressant-like eﬀects of capsaicin (100 lg/mouse)
in AW mice in the FST and splash test. There were
signiﬁcant diﬀerences between capsaicin
(100 lg/mouse) and capsaicin (100 lg/mouse) +
NMDA (7.5 mg/kg) administered groups in the FST
(P< 0.01, Fig. 6A) and splash test (P< 0.05, Fig. 6B).
Capsaicin and NMDA injections did not change the
behaviors of control animals in the FST and splash test
either alone or in combination (P> 0.05). Also,
capsaicin and NMDA treatments did not change total
distance moved and the number of rearings of both
experimental groups in the OF (P> 0.05, Fig. 6C, D).DISCUSSION
Results of this study have demonstrated that TRPV1
channels and NMDA receptors are involved in
depressive-like behaviors following AW. We showed
that antidepressant-like eﬀects of capsaicin are partially
mediated by NMDA receptors. Abuse of AMPH-like
drugs is a challenging dilemma which aﬀects large
number of people. Unfortunately, no eﬀective
pharmacological treatment has been yet introduced for
treatment of stimulants addiction and cognitive therapy
has achieved poor results in managing the condition
(Shoptaw et al., 2009; Chomchai and Chomchai, 2015).
Acute AMPH abstinence correlates with severe dysphoric
state that renders the drug seeking and relapses in with-
drawn individuals. It has been well-established that AW
induces potent depressive behaviors in both animals
and humans (Barr and Markou, 2005). In agreement with
previous investigations, we showed that AW mice exhib-
Fig. 4. Eﬀects of capsaicin and capsazepine co-administration on depressive-like behaviors. Eﬀects of capsaicin (100 lg/mouse, i.c.v.) and
capsazepine (100 lg/mouse, i.c.v.) co-administration on the immobility time in the FST (A), grooming activity time in the splash test (B), total
distance moved in the OF (C), and number of rearings in the OF (D) in the normal (control) and amphetamine-withdrawn (AW) animals. Values are
expressed as mean ± S.E.M and were analyzed using a one-way ANOVA followed by Tukey’s post hoc test. **P< 0.01 and ***P< 0.001
compared with the vehicle-treated control group (V group). ##P< 0.01 and ###P< 0.001 compared with the vehicle-treated withdrawn group (V
group). ^^P< 0.01 and ^^^P< 0.001 compared with the capsaicin (100 lg/mouse)-treated AW group.
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test. Increase in immobility time in the FST reﬂects the
behavioral despair and passive coping responses in
rodents in response to an inescapable stressful challenge
(Cryan and Holmes, 2005). Splash test has been reported
as a behavioral measure of the motivation and self-care
behaviors in rodents, in which poor response to the
sucrose (decrease in the grooming activity time) reﬂects
the diﬃculties in these behaviors (David et al., 2009;
Marrocco et al., 2014).
Growing body of evidence indicates that TRPV1
channels are involved in pathophysiology of the various
brain disorders such as addiction, mood and cognitive
diﬃculties (Martins et al., 2014; Aguiar et al., 2014).
These channels are widely distributed in brain structures
such as limbic system and cortical areas which are critical
regions of the brain involved in cognitive and behavioral
processes (Cristino et al., 2006; Edwards, 2014). Our
results revealed that administration of capsaicin and cap-
sazepine dose-dependently decreased the immobility
time in control mice. Also, we found that administration
of sub-eﬀective dose of capsaicin (and not capsazepine)possessed anti-depressant- like behaviors in FST and
splash test without changing the locomotor activity in
AW mice. Pretreatment with capsazepine reversed the
eﬀects of capsaicin suggesting that antidepressant-like
eﬀects of capsaicin are mediated by TRPV1 channels.
To explain the possible underlying mechanism(s) of
antidepressant-like eﬀects of capsaicin in AW mice,
recent clinical and preclinical investigations suggest that
decrease in dopaminergic tone and extracellular gluta-
mate levels are associated with depression following
abstinence of AMPH-like stimulants (Kalivas and
Volkow,2005; D’Souza and Markou, 2010). Evidence sug-
gests that AW-induced motivational diﬃculties are related
to impaired activity of dopaminergic system in mesocorti-
colimbic pathway (Koob, 1992; George et al., 2012; Der-
Avakian and Markou, 2012). It has been shown that
TRPV1 channels are expressed in dopaminergic neurons
in the several regions of the brain including hippocampus
and cortical areas (Cristino et al., 2006; Edwards, 2014).
Activation of TRPV1 channels is known to induce depolar-
ization in the neurons through enhancing the calcium
inﬂux (Madasu et al., 2015). In this regard, a study by
Fig. 5. Eﬀects of capsaicin and MK-801 co-administration on depressive-like behaviors. Eﬀects of capsaicin (10 lg/mouse, i.c.v.) and MK-801
(0.001 mg/kg, i.p.) co-administration on the immobility time in the FST (A), grooming activity time in the splash test (B), total distance moved in the
OF (C), and number of rearings in the OF (D) in the normal (control) and amphetamine-withdrawn (AW) animals. Values are expressed as mean
± S.E.M and were analyzed using a one-way ANOVA followed by Tukey’s post hoc test. *P< 0.01, **P< 0.01, and ***P< 0.001 compared with
the saline/vehicle-treated normal group (control S/V group). ###P< 0.001 compared with the saline/vehicle-treated withdrawn group (AW S/V
group).
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tion of TRPV1 channels by capsaicin increases dopamin-
ergic tone by activation of dopamine neurons in the
ventral tegmental area and nucleus accumbens
(Marinelli et al., 2005). Therefore, anti-withdrawal eﬀects
of capsaicin in AW mice may be associated with its pro-
moting eﬀect on dopaminergic activity. It is important to
note that clinical investigations for the treatment of
depression during psychostimulants withdrawal indicate
the eﬃcacy of pharmacological agents that targets
dopaminergic system such as amineptine (D’Souza and
Markou, 2010; Russo and Nestler, 2013).
Given the critical role of the glutamatergic system in
both addictive and depressive-like behaviors following
stimulants withdrawal (Kalivas and Volkow, 2005;
Zorumski and Izumi, 2012), we found that administration
of low doses of MK-801eﬀectively produced
antidepressant-like eﬀects in mice following AW. Consid-
ering that NMDA receptors play a critical role in patho-
physiology of depression, our results showed thathyper-sensitivity of the NMDA receptors after AW plays
a key role in mediation of depressive-like behaviors in ani-
mals. Our results were in line with recent studies that
have demonstrated ketamine, functional and non-
comparative NMDA receptor antagonist is able to attenu-
ate the AW-induced aﬀective-like behaviors in rodents
(Koltunowska et al., 2013; Belujon et al., 2015; Fuller
et al., 2015). Nevertheless, evidence indicates that
administration of NMDA receptor antagonists potently
enhances dopaminergic system activity in mesocorticol-
imbic circuits (Li et al., 2015; Cui et al., 2015). In this con-
text, an interesting research by Bartsch and colleagues
has recently revealed that hippocampal NMDA receptor
antagonists enhanced dopaminergic system activity
through a hippocampus-ventral tegmental area loop
(Bartsch et al., 2015). Thus, MK-801 not only is able to
improve dopaminergic tone, but also blocks NMDA recep-
tors that together may account for its antidepressant-like
eﬀects in AW mice. To support this, our results showed
that NMDA (7.5 mg/kg) could reverse the eﬀects of
Fig. 6. Eﬀects of capsaicin and NMDA co-administration on depressive-like behaviors. Eﬀects of capsaicin (100 lg/mouse, i.c.v.) and NMDA
(7.5 mg/kg, i.p.) co-administration on the immobility time in the FST (A), grooming activity time in the splash test (B), total distance moved in the OF
(C), and number of rearings in the OF (D) in the normal (control) and amphetamine-withdrawn (AW) animals. Values are expressed as mean ± S.E.
M and were analyzed using a one-way ANOVA followed by Tukey’s post hoc test. **P< 0.01 and ***P< 0.001 compared with the saline/vehicle-
treated normal group (control S/V group). ##P< 0.01 and ###P< 0.001 compared with the saline/vehicle-treated withdrawn group (AW S/V group).
^P< 0.05 and ^^P< 0.01 compared with the capsaicin (100 lg/mouse)-treated AW group.
S. Amiri et al. / Neuroscience 329 (2016) 122–133 131capsaicin in behavioral tests proposing that NMDA recep-
tors potently contribute to depressive-like behaviors fol-
lowing acute AW.
Furthermore, we found that unlike control animals, co-
administration of MK-801 and capsaicin at sub-eﬀective
doses exerted antidepressant-like eﬀects in AW mice
without aﬀecting locomotion. The synergistic eﬀects of
these drugs may be associated with their ability to
improve the impaired dopamine neurotransmission and
reward pathway. Our results were in line with previous
studies that have reported i.c.v (and not peripheral)
administration of capsaicin produced antidepressant-like
eﬀects in mice and NMDA receptors may mediate its
eﬀects (Hayase, 2011; Manna and Umathe 2012; Jang
et al., 2013). Further, there are previously published
investigations that are not consistent with our results.
These studies showed that activation of the TRPV1 chan-
nels was accompanied by depressive-like behaviors in
rodents (Abdelhamid et al., 2014; Navarria et al., 2014).
Inconsistency between the ﬁndings about the role of
TRPV1 receptors in depressive-like behaviors may be
attributed to conditions (physiologic/pathophysiologic) inwhich the behaviors were evaluated. Also, it is important
to note that those studies did not used the OFT (a neces-
sary test to validate the results of FST) to evaluate loco-
motor activity in experimental rodents. Thus, increased
immobility time following administration of TRPV1 ago-
nists in their experiments may be associated with direct
hypo-locomotion eﬀects of TRPV1 activation under phys-
iologic conditions.
On the other hand, it has been well-evident that
addiction to drugs of abuse is associated with
development of anxiety disorders (Lu¨thi and Lu¨scher,
2014). Evidence indicates that both TRPV1 and NMDA
receptors contribute to pathophysiology of anxiety disor-
ders (Zorumski and Izumi, 2012; Martins et al., 2014). In
this regard, it has been reported that activation of TRPV1
receptors is associated with anxiogenic behaviors while;
blockade of these channels produces anxiolytic eﬀects.
However, a comprehensive review by Madasu and col-
leagues have demonstrated that activation/blockade of
TRPV1 receptors has diﬀerent eﬀects on anxiety-like
behaviors regarding the site of drug injection (Madasu
et al., 2015). Further, NMDA receptor antagonists have
132 S. Amiri et al. / Neuroscience 329 (2016) 122–133been reported to have anxiolytic eﬀects in both human
and rodents (Barkus et al., 2010). However, a recent
study by Haj-Mirzaian et al. showed that NMDA receptor
antagonists (such as ketamine and MK-801) were able
to attenuate depressive-like behaviors (and not anxiety-
like behaviors) is socially isolated mice (Haj-Mirzaian
et al., 2015). Our study also has limitations because we
used only male mice in this study. In fact, our reason to
use male mice was that most amphetamine addicts/abu-
sers are men. However, evidence indicates that there
are signiﬁcant diﬀerences between men and women in
tendency to rewarding eﬀects of drugs of abuse (Fattore
et al., 2014; Bobzean et al., 2014). In addition, we did
not evaluate the role of other glutamate receptors in this
work. Previous investigations have reported that AMPA
receptors are also involved in pathophysiology of depres-
sion and addiction (Chourbaji et al., 2008; Fumagalli et al.,
2011; Vogt et al., 2014; Chen and Chen, 2015). Similarly,
meabotropic glutamate receptor (mGluR) 5 is involved in
pathophysiology of both mood and addiction disorders
(Osborne and Olive, 2008; Inta et al., 2013). Furthermore,
mGluR7 has been suggested as a therapeutic target for
treatment of psychostimulant addiction (Li and Markou,
2015).CONCLUSION
In present study we found that both MK-801 and
capsaicin are able to mitigate depressive-like behaviors
following AW in male mice. Further, NMDA receptors, at
least partially, play a role in anti-withdrawal eﬀects of
capsaicin. Further studies seem warranted to
understand mechanisms which are involved in
depressive-like behaviors following AMPH-like drugs.
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